Bridging the gap – estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel
Preprint
Abstract
Throughout the SARS-CoV-2 pandemic, Germany lacked an adaptive population panel for epidemic diseases and a modelling platform to rapidly incorporate panel estimates. We evaluated how a cross-sectional analysis of 9922 participants of the MuSPAD study in June/July 2022 combined with a newly developed modelling platform could bridge the gap and analyzed antibody levels, neutralizing serum activity and interferon-gamma release response of serum samples. We categorized the population into four groups with differing protection against severe course of disease (validated by neutralizing serum activity), and found that 30% were in the group with highest protection, and 85% in either the highest categories or second highest group regarding protection level. Estimated hospitalizations due to SARS-CoV-2 were predicted to be between 30 to 300% of the peak in 02/2021 dependent on assumed variant characteristics. We showed the feasibility of a rapid epidemic panel able to evaluate complex endpoints for SARS-CoV-2 and inform scenario modelling.Keywords
All Related Versions
- Published version: International Journal of Infectious Diseases, 139, 50.
This publication has 27 references indexed in Scilit:
- Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditionsRheumatology, 2022
- Age-specific Contribution of Contacts to Transmission of SARS-CoV-2 in GermanymedRxiv, 2021
- Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or VaccinationClinical Infectious Diseases, 2021
- Long Term Accuracy of SARS-CoV-2 Interferon-γ Release Assay and its Application in Household InvestigationmedRxiv, 2021
- Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adultsmedRxiv, 2021
- SARS-CoV-2 infections in kindergartens and associated households at the start of the second wave in Berlin, Germany—a cross-sectional studyEuropean Journal of Public Health, 2021
- Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19Journal of Neurology, 2021
- Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, GermanyNature Communications, 2021
- Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020medRxiv, 2021
- SARS-CoV-2 transmissions in students and teachers: seroprevalence follow-up study in a German secondary school in November and December 2020BMJ Paediatrics Open, 2021